PET scan to see if chemoradiation is working for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial uses a special PET/CT scan to see how well your esophageal cancer responds to chemotherapy and radiation. It helps doctors find out if the treatment is working early on.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have untreated esophageal cancer that is larger than 2 cm and will be treated with chemotherapy and radiation.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control.
- You have no history of allergic reaction to CT contrast dye.
- Your kidney function is good enough (eGFR at least 40) within the last month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new PET scan drug (18F-FAPI) to see if it can better detect where stomach or esophageal cancer has spread. It may help doctors plan the right treatment for you.
This study looks at whether detailed scans taken before treatment can predict how well chemo and immunotherapy will work for advanced esophageal cancer. The goal is to improve treatment planning and potentially reduce side effects by personalizing care.
This Phase 1 study uses specialized imaging (including MRI) to better “see” low-oxygen areas in esophageal cancer and help guide individualized radiation treatment. It aims to improve how radiation is planned and delivered while checking safety.
This trial tests whether a special PET scan called FAPI-PET can better show the edges of esophageal tumors before surgery. It may help doctors plan more precise surgery.
This study tests whether a special imaging scan (functional imaging) can identify which esophageal cancers respond best to radiation. If you have stage II–IVA esophageal cancer and meet the health criteria, joining may help personalize your treatment.
This trial studies a new way to see how an antibody (AK112) spreads in esophageal cancer tumors using a PET scan. It might help doctors better understand your cancer and guide future treatment.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.